Jean-Marc Treluyer

Jean-Marc Treluyer

Auto-generated profile, based on publicly available information

Jean-Marc Treluyer

Department of Clinical Pharmacology Cochin Hospital Paris Ile‐de‐France France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Rheumatology
Verified
Journal Article
Open access
PDF file
CMCamille Mettler
Camille Mettler
AJAnnie-Pierre Jonville-Bera
Annie-Pierre Jonville-Bera
AGAurélie Grandvuillemin
Aurélie Grandvuillemin
JTJean-Marc Treluyer
Jean-Marc Treluyer
BTBenjamin Terrier
Benjamin Terrier
LCLaurent Chouchana
Laurent Chouchana
Camille Mettler, Annie-Pierre Jonville-Bera, Aurélie Grandvuillemin, Jean-Marc Treluyer, Benjamin Terrier, Laurent Chouchana; Risk of giant cell arteritis and p

24 March 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ABAnne-Sophie Bonnel
Anne-Sophie Bonnel
TBTiphaine Bihouée
Tiphaine Bihouée
MRMélanie Ribault
Mélanie Ribault
MDMarine Driessen
Marine Driessen
DGDavid Grèvent
David Grèvent
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus

27 September 2018 in Trials
Verified
Journal Article
Open access
PDF file
FRFrancesca Maria Russo
Francesca Maria Russo
ABAlexandra Benachi
Alexandra Benachi
TMTim Van Mieghem
Tim Van Mieghem
JHJan De Hoon
Jan De Hoon
KCKristel Van Calsteren
Kristel Van Calsteren
JDJan Deprest
Jan Deprest
Congenital diaphragmatic hernia is an orphan disease with high neonatal mortality and significant morbidity. An important cause for this is pulmonary hypertension, for which no effective postnatal therapy is available to date. An innovative strategy aiming at treating or preventing pulmonary hypertension more effectively is urgently needed. Prenatal sildenafil administration to expectant mothers prevented fetal and neonatal vascular changes leading to pulmonary hypertension in several animal models, and is, therefore, a promising approach. Before transferring this antenatal medical approach to the clinic, more information is needed on transplacental transfer and safety of sildenafil in humans. This is a randomized, investigator-blinded, double-armed, parallel-group, phase I/IIb study with as a primary objective to measure the in-vivo transplacental transfer of sildenafil in women in the second and early third trimester of pregnancy (sub-study 1; weeks: 20.0–32.6) and at term (sub-study 2; weeks: 36.6–40). Participants will be randomized to two different sildenafil doses: 25 or 75 mg. In sub-study 1, a single dose of the investigational product will be administered to women undergoing termination of pregnancy, and maternal and fetal blood samples will be collected for determination of sildenafil concentrations. In sub-study 2, sildenafil will be administered three times daily from 3 days before planned delivery until actual delivery, following which maternal and umbilical cord samples will be collected. Proxies of maternal and fetal tolerance as well as markers of fetal pulmonary vasodilation will also be measured. This is the first study evaluating in-vivo transplacental passage of sildenafil in humans. EU Clinical Trials Register 2016–002619-17, validated on 12 August 2016. Trial sponsor: UZ Leuven, Herestraat 49, 3000 Leuven.

28 February 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
LPLaure‐Hélène Préta
Laure‐Hélène Préta
ACAdrien Contejean
Adrien Contejean
FSFrancesco Salvo
Francesco Salvo
JTJean‐Marc Treluyer
Jean‐Marc Treluyer
CCCaroline Charlier
Caroline Charlier
LCLaurent Chouchana
Laurent Chouchana
Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and first epidemiological evidences suggest an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. Until 30th June 2021, of 716,928 reports with mRNA COVID-19 vaccines, we found 7,728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds-ratio 1.9, 95%CI [1.8-2.1]). Furthermore, we found a reduced risk of reporting HZ among under 40 year-old persons compared to older persons (reporting odds-ratio 0.39, 95%CI [0.36-0.41]). Mild and infrequent HZ reactions may occur shortly after mRNA COVID-19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 year-old. Further analyses are needed to confirm this risk.

9 March 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
LCLaurent Chouchana
Laurent Chouchana
MCMathis Collier
Mathis Collier
CMClémence Martin
Clémence Martin
PBPierre-Régis Burgel
Pierre-Régis Burgel
JTJean-Marc Treluyer
Jean-Marc Treluyer
Recent therapeutic advances, mainly with the advent of CFTR modulators, have been associated with an increasing number of pregnancies in females with cystic fibrosis (fwCF). This study aimed to evaluate the safety of the use of CFTR modulators, specifically elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) during pregnancy. A nationwide cohort study was conducted using the French health insurance data warehouse (SNDS), covering nearly all singleton pregnancies ending between January 2018 and December 2023. Exposure to CFTR modulators was defined as using prescriptions through pregnancy, including one month in the preconception period. The study compared pregnancy outcomes amongst fwCF between pregnancies exposed and unexposed to CFTR modulators. Among 590 pregnancies in fwCF, 148 (24.7 %) were exposed to CFTR modulators, including 136 during first trimester. Of these, 147 (99.3 %) resulted in livebirths. The most common CFTR modulator used was ELX/TEZ/IVA, in 121 (81.8 %) pregnancies. The prevalence of major birth defects was similar between exposed and unexposed fwCF (3.38 % vs. 4.66 %; p = 0.72). The rate of small for gestational age (SGA, <10th percentile) was significantly lower in pregnancies exposed compared to unexposed (6.8 % vs. 16.1 %; p < 0.01). The study provides early reassurance about the safety of CFTR modulators during pregnancy, particularly in terms of teratogenicity and adverse pregnancy outcomes. While findings suggest potential benefits, such as halved rate of SGA, further research is required to confirm these outcomes and investigate long-term effects on the development of children prenatally exposed to CFTR modulators.

1 February 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
ACAdrien Contejean
Adrien Contejean
MTMylène Tisseyre
Mylène Tisseyre
ECEtienne Canouï
Etienne Canouï
JTJean-Marc Treluyer
Jean-Marc Treluyer
SKSolen Kerneis
Solen Kerneis
LCLaurent Chouchana
Laurent Chouchana
Background: Excess of acute kidney injury (AKI) secondary to the association of vancomycin plus piperacillin is debated. Objectives: To detect a signal for an increased risk of AKI with the vancomycin and piperacillin combination compared with other vancomycin-based regimens. Methods: Using VigiBase, the WHO global database of individual case safety reports (ICSR) from 1997 to 2019, we conducted a disproportionality analysis comparing the reporting of AKI cases between different vancomycin-based regimens (vancomycin plus piperacillin, cefepime or meropenem). To take into account a possible notoriety bias, we secondarily restricted the study period to before 2014, the date of the first publication of AKI in patients receiving vancomycin plus piperacillin. Results are expressed using the reporting OR (ROR) and its 95% CI. Results: From 1997 to 2019, 53 701 ICSR concerning vancomycin have been registered in the database, including 6016 reports of AKI (11.2%), among which 925 (15.4%) were reported with vancomycin/piperacillin, 339 (5.6%) with vancomycin/cefepime and 197 (3.7%) with vancomycin/meropenem. ROR (95% CI) for AKI was 2.6 (2.4–2.8) for vancomycin/piperacillin, 2.5 (2.2–2.9) for vancomycin/cefepime and 0.5 (0.4–0.6) for vancomycin/meropenem versus other vancomycin-containing regimens. After restriction of the study period to 1997–2013, the ROR for AKI remains significant only for vancomycin/piperacillin [ROR (95% CI) = 2.1 (1.8–2.4)]. Conclusions: We found a disproportionality in reports of AKI in patients receiving vancomycin plus piperacillin compared with vancomycin in other regimens. This suggests a drug–drug interaction between these two antibiotics resulting in an increased risk of AKI.